Lastly, although our findings demonstrate the efficacy of anti-CD21 CAR-T cells in relevant preclinical models of T-ALL, well-designed clinical trials will be necessary to confirm their potential in patients. This evidence concerns the gene CR2 and acute lymphoblastic leukemia.